These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 23235168)

  • 1. [A new horizon in the treatment of head and neck cancer - anti-epidermal growth factor receptor monoclonal antibodies as novel options].
    Tahara M; Fujii M
    Gan To Kagaku Ryoho; 2012 Dec; 39(13):2489-507. PubMed ID: 23235168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EGFR monoclonal antibodies in locally advanced head and neck squamous cell carcinoma: What is their current role?
    Alorabi M; Shonka NA; Ganti AK
    Crit Rev Oncol Hematol; 2016 Mar; 99():170-9. PubMed ID: 26797287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancers.
    Vokes EE; Chu E
    Oncology (Williston Park); 2006 Apr; 20(5 Suppl 2):15-25. PubMed ID: 16736979
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cetuximab: a review of its use in squamous cell carcinoma of the head and neck.
    Frampton JE
    Drugs; 2010 Oct; 70(15):1987-2010. PubMed ID: 20883055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New approaches to EGFR inhibition for locally advanced or metastatic squamous cell carcinoma of the head and neck (SCCHN).
    Agulnik M
    Med Oncol; 2012 Dec; 29(4):2481-91. PubMed ID: 22252310
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted therapy in head and neck cancer: state of the art 2007 and review of clinical applications.
    Langer CJ
    Cancer; 2008 Jun; 112(12):2635-45. PubMed ID: 18442098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overview of Current Treatment Options and Investigational Targeted Therapies for Locally Advanced Squamous Cell Carcinoma of the Head and Neck.
    Zibelman M; Mehra R
    Am J Clin Oncol; 2016 Aug; 39(4):396-406. PubMed ID: 26967327
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cetuximab in the treatment of head and neck cancer.
    Bernier J
    Expert Rev Anticancer Ther; 2006 Nov; 6(11):1539-52. PubMed ID: 17134359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cetuximab in squamous cell carcinoma of the head and neck.
    Hitt R; Martín P; Hidalgo M
    Future Oncol; 2006 Aug; 2(4):449-57. PubMed ID: 16922611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody for treatment of head and neck cancer.
    Herbst RS; Hong WK
    Semin Oncol; 2002 Oct; 29(5 Suppl 14):18-30. PubMed ID: 12422310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of inhibitors of the epidermal growth factor in management of head and neck cancer.
    Brockstein B; Lacouture M; Agulnik M
    J Natl Compr Canc Netw; 2008 Aug; 6(7):696-706. PubMed ID: 18691458
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.
    Harding J; Burtness B
    Drugs Today (Barc); 2005 Feb; 41(2):107-27. PubMed ID: 15821783
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cetuximab in metastatic or recurrent head and neck cancer: the EXTREME trial.
    Rivera F; García-Castaño A; Vega N; Vega-Villegas ME; Gutiérrez-Sanz L
    Expert Rev Anticancer Ther; 2009 Oct; 9(10):1421-8. PubMed ID: 19828002
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer.
    Jean GW; Shah SR
    Pharmacotherapy; 2008 Jun; 28(6):742-54. PubMed ID: 18503402
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidermal growth factor receptor directed therapy in head and neck cancer.
    Choong NW; Cohen EE
    Crit Rev Oncol Hematol; 2006 Jan; 57(1):25-43. PubMed ID: 16207530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multicenter Phase II Study of Panitumumab in Platinum Pretreated, Advanced Head and Neck Squamous Cell Cancer.
    Siano M; Molinari F; Martin V; Mach N; Früh M; Freguia S; Corradino I; Ghielmini M; Frattini M; Espeli V
    Oncologist; 2017 Jul; 22(7):782-e70. PubMed ID: 28592616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of advanced head and neck cancer with cetuximab.
    Merlano M; Garrone O
    Int J Biol Markers; 2007; 22(1 Suppl 4):S71-6. PubMed ID: 17520584
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug Insight: cetuximab in the treatment of recurrent and metastatic squamous cell carcinoma of the head and neck.
    Bernier J
    Nat Clin Pract Oncol; 2008 Dec; 5(12):705-13. PubMed ID: 18825142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New trends in epidermal growth factor receptor-directed monoclonal antibodies.
    Markman B; Capdevila J; Elez E; Tabernero J
    Immunotherapy; 2009 Nov; 1(6):965-82. PubMed ID: 20635913
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting epidermal growth factor receptor in head and neck cancer: lessons learned from cetuximab.
    Moon C; Chae YK; Lee J
    Exp Biol Med (Maywood); 2010 Aug; 235(8):907-20. PubMed ID: 20562132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.